
|Videos|July 19, 2023
Treating MDS with Erythropoiesis-Stimulating Agents (ESAs)
Author(s)Amy Dezern, MD, MHS
Amy Dezern, MD, MHS, details her experience with using erythropoiesis stimulating agents for the treatment of MDS in her clinical practice.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5

















